Abstracts tagged "Health care cost"

Abstract Number: 1238 • 2016 ACR/ARHP Annual Meeting
Assessment of Mortality and Healthcare Costs Associated with Systemic Sclerosis with and without Lung Involvement
Karina Raimundo¹, Amanda Farr², Ashley Cole³ and Aryeh Fischer⁴, ¹Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ²Truven Health Analytics, Cambridge, MA, ³Truven Health Analytics, Bethesda, MD, ⁴Medicine / Center for Lungs and Breathing, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Patients with systemic sclerosis (SSc) are at high risk of developing interstitial lung disease (ILD) and/or pulmonary hypertension (PH). These two lung manifestations are…
Abstract Number: 1240 • 2016 ACR/ARHP Annual Meeting
A Minority of Patients Utilize Most of Healthcare Resources in Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, and Axial Spondyloarthritis
Nina Mars¹, Anne M Kerola², Markku J Kauppi^3,4, Outi Elonheimo^5,6, Santeri Huvinen^5,6 and Tuulikki Sokka-Isler^7,8, ¹University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³School of Medicine, University of Tampere, Tampere, Finland, ⁴Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁵Network of Academic Health Centres, Department of Medicine, University of Helsinki, Helsinki, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁸RAID working group for EULAR, Zurich, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare costs, but little is known about how the costs compare to other chronic rheumatic diseases. We…
Abstract Number: 113 • 2015 ACR/ARHP Annual Meeting
Longitudinal, Incremental Direct Medical Costs of Giant Cell Arteritis for the First Five Years Following Diagnosis: A General Population-Based Cohort Study
Natalie McCormick¹, Carlo Marra² and J Antonio Avina-Zubieta³, ¹Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Giant cell arteritis (GCA) is the most common form of adult vasculitis, but estimates of the healthcare costs of GCA are extremely scarce. We…
Abstract Number: 989 • 2015 ACR/ARHP Annual Meeting
Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis
Megan Barber¹, John G. Hanly², Aidan O'Keeffe³, Li Su⁴, Murray Urowitz^5,6, Yvan St. Pierre⁷, Juanita Romero-Diaz⁸, C. Gordon⁹, Sang-Cheol Bae¹⁰, Sasha Bernatsky¹¹, Daniel J Wallace¹², Joan T. Merrill¹³, David A. Isenberg¹⁴, Anisur Rahman¹⁵, Ellen M. Ginzler¹⁶, Paul R. Fortin¹⁷, Dafna D. Gladman¹⁸, Jorge Sanchez-Guerrero¹⁹, Michelle Petri²⁰, Ian N. Bruce²¹, Mary Anne Dooley²², Rosalind Ramsey-Goldman²³, Cynthia Aranow²⁴, Graciela S. Alarcon²⁵, W. Winn Chatham²⁶, Kristján Steinsson²⁷, Ola Nived²⁸, Gunnar K. Sturfelt²⁹, Susan Manzi³⁰, Munther Khamashta³¹, Ronald F. van Vollenhoven³², Asad Zoma³³, Manel Ramos-Casals³⁴, Guillermo Ruiz-Irastorza³⁵, S. Sam Lim³⁶, Thomas Stoll³⁷, Murat Inanc³⁸, Kenneth C. Kalunian³⁹, Diane L. Kamen⁴⁰, Peter Maddison⁴¹, Christine A. Peschken⁴², Søren Jacobsen⁴³, Anca Askanase⁴⁴, Jill P. Buyon⁴⁵, Chris Theriault⁴⁶, Kara Thompson⁴⁶, Vernon Farewell⁴⁷ and Ann E. Clarke⁴⁸, ¹Division of Rheumatology, University of Calgary, Caglary, AB, Canada, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Statistical Science, University College London, London, United Kingdom, ⁴MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK, Cambridge, United Kingdom, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁸Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico, ⁹School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁰Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹¹Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ¹²Cedars-Sinai Medical Center, West Hollywood, CA, ¹³Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁵Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ¹⁶Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁷Rheumatology, University of Laval, Quebec, QC, Canada, ¹⁸Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²⁰Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²¹Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²²UNC Kidney Centre, Chapel Hill, NC, ²³Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁴Feinstein Institute for Medical Research, Mahasset, NY, ²⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁶Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²⁷Centre for Rheumatology Research, Landspital University Hospital, Reykjavik, Iceland, ²⁸Rheumatology, Inst of Clinical sciences, Lund, Sweden, ²⁹Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ³⁰Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³¹Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³³Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ³⁵Autoimmune Disease Research Unit, Service of Internal Medicine, Hospital de Cruces, UPV/EHU, Barakaldo, Spain, ³⁶Emory University School of Medicine, Atlanta, GA, ³⁷Abteilung Rheumatologie/Rehab, Kantonsspital Schaffhausen, Schaffhausen, Switzerland, ³⁸Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁹Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ⁴⁰Medicine, Medical University of South Carolina, Charleston, SC, ⁴¹Musculoskeletal Medicine, Bangor University, Bangor, United Kingdom, ⁴²Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ⁴³Department of Rheumatology,, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁴⁴Columbia University College of Physicians & Surgeons, New York, NY, ⁴⁵Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴⁶Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴⁷Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁴⁸Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Little is known about the long-term costs of lupus nephritis (LN). The annual and long-term healthcare costs were compared between SLE patients with and…
Abstract Number: 1270 • 2015 ACR/ARHP Annual Meeting
Low Socioeconomic Status As a Predictor of Long-Term Direct Medical Costs Following Diagnosis of Granulomatosus with Polyangiitis: A General Population-Based Cohort Study
Natalie McCormick¹, Carlo Marra² and J Antonio Avina-Zubieta³, ¹Faculty of Pharmaceutical Sciences, University of British Columbia/Arthritis Research Canada, Vancouver, BC, Canada, ²Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Estimates of the healthcare costs of Granulomatosus with polyangiitis (GPA) and predictors of costs are scarce. In particular, while socioeconomic status (SES) is associated…
Abstract Number: 1280 • 2015 ACR/ARHP Annual Meeting
Comparison of Health Service Utilization Costs Between Aboriginal and Non-Aboriginal Patients with Rheumatoid Arthritis Requiring Biologic Therapy
Cheryl Barnabe¹, Yufei Zheng², Arto Ohinmaa², Brenda Hemmelgarn³, Gilaad Kaplan⁴, Liam Martin⁵ and Walter Maksymowych⁶, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Institute of Health Economics, Edmonton, AB, Canada, ³Division of Nephrology, University of Calgary, Calgary, AB, Canada, ⁴Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Medicine, Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Logistical issues and poor cultural environments in tertiary care create barriers to specialized care for Aboriginal patients with rheumatoid arthritis (RA). Aboriginal patients are…
Abstract Number: 2103 • 2015 ACR/ARHP Annual Meeting
Temporal Trends in Drug Prescription, Utilization and Costs Among Rheumatoid Arthritis (RA) Patients Show Wide Regional Variation Despite Universal Drug Coverage
Mark Tatangelo¹, Michael Paterson², George A. Tomlinson³, Nick Bansback⁴, Jessica Widdifield⁵, Tara Gomes² and Claire Bombardier⁶, ¹University of Toronto, Toronto, ON, Canada, ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ³Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶18 Strathearn Blvd, University of Toronto, Toronto, ON, Canada
Background/Purpose: Monitoring of drug use and costs can: describe trends in expenditures over time, identify regional variations in access and indicate physicians' uptake of best-practice…
Abstract Number: 2535 • 2015 ACR/ARHP Annual Meeting
Increased Direct Healthcare Costs in SLE Pregnancies
Cristiano Moura¹, Sasha Bernatsky², Yvan St. Pierre³, Susan Scott³, Christian A. Pineau⁴, Ann E. Clarke⁵ and Evelyne Vinet⁴, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁵Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Although adverse obstetrical complications are more frequent in SLE women, no one has evaluated healthcare costs during SLE pregnancies. Thus, we aimed to evaluate…
Abstract Number: 2118 • 2014 ACR/ARHP Annual Meeting
Lower Socioeconomic Status at Disease Onset Is Associated with Higher Health Care Costs in Patients with Systemic Lupus Erythematosus: A General Population-Based Cohort Study
Natalie McCormick¹, Mohsen Sadatsafavi², Wenjia Chen³, Carlo A. Marra⁴ and J. Antonio Avina-Zubieta⁵, ¹Faculty of Pharmaceutical Sciences, University of British Columbia/Arthritis Research Centre of Canada, Vancouver, BC, Canada, ²Division of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada, ³Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁴Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: Low socioeconomic status (SES) negatively impacts health outcomes in the general population, as well as in systemic lupus erythematosus (SLE), but the impact on…
Abstract Number: 1094 • 2014 ACR/ARHP Annual Meeting
Work Productivity and Healthcare Utilization in Patients with Fibromyalgia and Comorbid Depression Taking Antidepressant Medication
Jaren Landen¹, Claire Burbridge², Elizabeth Masters³, Pritha Bhadra Brown⁴, Joseph Scavone¹, Birol Emir⁴, Richard Vissing⁵, Andrew Clair⁴ and Lynne Pauer⁶, ¹Pfizer Inc, Groton, CT, ²Pfizer Ltd, Walton Oaks, United Kingdom, ³Health Economics and Outcomes Research, Pfizer Inc, New York, NY, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Louisville, KY, ⁶445 Eastern Point Road, Pfizer Inc, Groton, CT
Background/Purpose Patients with fibromyalgia (FM) experience pain, sleep disruption, fatigue, and other symptoms that limit activity, impacting work productivity and increasing healthcare utilization. Here, we…
Abstract Number: 116 • 2014 ACR/ARHP Annual Meeting
Is Socioeconomic Status at Diagnosis Associated with Long-Term Direct Medical Costs in Systemic Sclerosis? a General Population-Based Cohort Study
Natalie McCormick¹, Mohsen Sadatsafavi², Wenjia Chen³, Carlo A. Marra⁴ and J. Antonio Avina-Zubieta⁵, ¹Faculty of Pharmaceutical Sciences, University of British Columbia/Arthritis Research Centre of Canada, Vancouver, BC, Canada, ²Division of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada, ³Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁴Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: Low socioeconomic status (SES) is associated with negative health outcomes and higher healthcare costs in general populations, but the impact of SES on costs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].